Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,059 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,059 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02410174 | To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma… | Phase 1 | terminated | Apr 7, 2015 | Beth Israel Medical Center | Poor Accural | Other (stated, no rule matched) |
| NCT02213744 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in…(HERMIONE) | Phase 2 / Phase 3 | terminated | Aug 11, 2014 | Merrimack Pharmaceuticals | Felt not to show benefit over control per DMC and confirmed via futility analysis | Efficacy / futility |
| NCT02331875 | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the… | Phase 1 / Phase 2 | terminated | Jan 6, 2015 | Innate Pharma | lack of recruitment | Enrollment / accrual |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | Phase 2 | terminated | Jun 16, 2011 | Novartis Pharmaceuticals | The study was stopped for not meeting the primary endpoint for PFS. | Other (stated, no rule matched) |
| NCT00598858 | Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the…(2007-5904) | Phase 2 | withdrawn | Jan 23, 2008 | John P. Fruehauf | Halted due to zero accrual and lack of funding | Enrollment / accrual |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously… | Phase 1 / Phase 2 | withdrawn | Jan 22, 2016 | Case Comprehensive Cancer Center | Drug unavailable | Other (stated, no rule matched) |
| NCT01875198 | Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected… | N/A | terminated | Jun 11, 2013 | Yonsei University | because of difficulties of enrolling appropriate participants | Enrollment / accrual |
| NCT01335074 | Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | withdrawn | Apr 13, 2011 | Philipps University Marburg | not stated | Not stated |
| NCT00427973 | AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer | Phase 2 | terminated | Jan 29, 2007 | National Cancer Institute (NCI) | The study was stopped prior to 2nd stage. | Other (stated, no rule matched) |
| NCT01283178 | Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced… | Phase 1 | terminated | Jan 25, 2011 | Virginia Commonwealth University | The study was terminated. The data analysis was futile with only 3 accruals. PI opted to terminate… | Enrollment / accrual |
| NCT01144169 | Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma | Phase 1 | terminated | Jun 15, 2010 | University of Pittsburgh | barriers to accrual: delay until surgery and additional pre-operative visits | Enrollment / accrual |
| NCT00061178 | Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma | Phase 3 | withdrawn | May 23, 2003 | Genentech, Inc. | No patients were enrolled, study cancelled before start | Enrollment / accrual |
| NCT02279576 | Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)(PAZOPEN-SOGUG) | Phase 2 | terminated | Oct 31, 2014 | Spanish Oncology Genito-Urinary Group | The low recruitment of patients will not allow to complete the study with the required number of… | Enrollment / accrual |
| NCT01123473 | Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without… | Phase 2 | terminated | May 14, 2010 | European Organisation for Research and Treatment of Cancer - EORTC | company withdrew interest | Sponsor / business decision |
| NCT02287727 | Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have… | Phase 2 | withdrawn | Nov 11, 2014 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT02649530 | A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous… | Phase 2 | withdrawn | Jan 7, 2016 | University of Michigan Rogel Cancer Center | funding withdrawn | Funding |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Phase 1 | terminated | Apr 11, 2013 | Mirna Therapeutics, Inc. | Five immune related serious adverse events | Safety / toxicity |
| NCT00201734 | Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and… | Phase 1 / Phase 2 | terminated | Sep 20, 2005 | Ohio State University Comprehensive Cancer Center | Due to lack of funding provided for Phase II portion of trial | Funding |
| NCT00190554 | A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous… | Phase 3 | terminated | Sep 19, 2005 | Japan Clinical Oncology Group | not stated | Not stated |
| NCT02078843 | Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide…(GaIN) | Phase 1 / Phase 2 | terminated | Mar 5, 2014 | Insel Gruppe AG, University Hospital Bern | Superiority of one imaging method | Other (stated, no rule matched) |
| NCT01964235 | Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma | Phase 2 | withdrawn | Oct 17, 2013 | Novartis Pharmaceuticals | Study was cancelled by Sponsor. | Other (stated, no rule matched) |
| NCT01975688 | A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis | Phase 1 | terminated | Nov 5, 2013 | GW Pharmaceuticals Ltd | Slow recruitment | Enrollment / accrual |
| NCT02539017 | The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast… | Phase 2 | withdrawn | Sep 2, 2015 | First Affiliated Hospital Xi'an Jiaotong University | because of safety problem, this trial was stopped in the hospital | Safety / toxicity |
| NCT01820312 | A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) | Phase 2 | withdrawn | Mar 28, 2013 | University of Arkansas | Due to no enrollment. | Enrollment / accrual |
| NCT01528137 | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer… | Phase 1 | terminated | Feb 7, 2012 | Stanford University | Negative data from another trial led to termination of this trial by sponsor. | Other (stated, no rule matched) |
| NCT01020812 | Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | terminated | Nov 26, 2009 | Stanford University | enrollment was too low | Enrollment / accrual |
| NCT00318110 | Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Apr 26, 2006 | Center for International Blood and Marrow Transplant Research | Unable to meet subject enrollment goal. | Enrollment / accrual |
| NCT02334319 | Ganetespib Window of Opportunity Study in Head and Neck Cancers | Phase 1 | terminated | Jan 8, 2015 | Emory University | Lack of funding | Funding |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced… | Phase 1 | withdrawn | Dec 11, 2015 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT01137162 | Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors | — | terminated | Jun 4, 2010 | Stanford University | Low Accrual | Enrollment / accrual |
| NCT00627835 | Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and… | Phase 1 | withdrawn | Mar 3, 2008 | British Columbia Cancer Agency | Site decided not to open this study | Other (stated, no rule matched) |
| NCT00377247 | Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With… | Phase 1 | terminated | Sep 18, 2006 | University of Pittsburgh | study closed to accrual due to slow accrual | Enrollment / accrual |
| NCT02152059 | A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer… | Phase 2 | withdrawn | Jun 2, 2014 | AHS Cancer Control Alberta | contract issues | Other (stated, no rule matched) |
| NCT01326390 | Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular… | — | terminated | Mar 30, 2011 | Stanford University | not stated | Not stated |
| NCT00800969 | Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of… | Phase 2 | withdrawn | Dec 3, 2008 | University of Zurich | not stated | Not stated |
| NCT01048086 | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) | Phase 2 | withdrawn | Jan 13, 2010 | University of Iowa | No patients were enrolled because the company that pledged the drug does not yet have it available. | Enrollment / accrual |
| NCT01911416 | A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog… | N/A | withdrawn | Jul 30, 2013 | University of Utah | No accrual | Enrollment / accrual |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Oct 14, 2015 | Roswell Park Cancer Institute | drug supply issues | Drug supply |
| NCT02351505 | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | Phase 2 | terminated | Jan 30, 2015 | Erin Bertino | Low patient accrual | Enrollment / accrual |
| NCT01755182 | Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver…(LOTUS) | Phase 3 | terminated | Dec 24, 2012 | National Cancer Institute, Naples | difficulty enrollment, no patients received treatment | Enrollment / accrual |
| NCT00971126 | Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | terminated | Sep 3, 2009 | National Health Research Institutes, Taiwan | Two patients in the first dose level be counted as reaching DLT. DSMB recommend terminated early… | Other (stated, no rule matched) |
| NCT01480817 | Sorafenib VS TACE in HCC Patients With Portal Vein Invasion | Phase 2 | terminated | Nov 29, 2011 | Seoul National University Hospital | Difficulty of participant enrollment. | Enrollment / accrual |
| NCT01857726 | Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With… | N/A | withdrawn | May 20, 2013 | Seoul National University Hospital | No participants were enrolled | Enrollment / accrual |
| NCT01953406 | The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of… | Phase 2 | withdrawn | Oct 1, 2013 | Seoul National University Hospital | No participants were enrolled. Therefore, we stop this study, prematurely. | Enrollment / accrual |
| NCT02004210 | A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma | Phase 3 | withdrawn | Dec 9, 2013 | Seoul National University Hospital | No participants were enrolled. | Enrollment / accrual |
| NCT01875549 | Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary… | N/A | withdrawn | Jun 12, 2013 | Kwang Hyuck Lee | no enrollment | Enrollment / accrual |
| NCT01807156 | Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer | Phase 2 | terminated | Mar 8, 2013 | Emory University | Primary endpoint not met | Other (stated, no rule matched) |
| NCT02119728 | Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the… | Phase 2 | withdrawn | Apr 22, 2014 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT02143622 | Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell… | Phase 1 / Phase 2 | withdrawn | May 21, 2014 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical…(iNSITE2) | Phase 2 | terminated | Jun 24, 2015 | BIND Therapeutics | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 9, 2017source: clinicaltrials